Yousuf Zafar, MD, will advise The Samfund on research and evaluation of data to enhance its ability to combat financial aftereffects of cancer treatment.
The Samfund has announced the addition of Yousuf Zafar, MD, associate professor of medicine and public policy, and a gastrointestinal oncologist at the Duke Cancer Institute, to its advisory council. Zafar will advise The Samfund on research and evaluation of data to enhance its ability to combat financial aftereffects of cancer treatment.
Costs associated with cancer treatment can be a significant burden in a young adult cancer survivor’s life. Research conducted by The Samfund has found that the average net worth of a young adult cancer survivor receiving grants from the organization is approximately -$35,000, compared with $68,000 for young adults in the general population.
“While cancer treatment is evolving and improving, innovation comes at a high price,” Zafar said. "Every day, patients are making sacrifices to afford their cancer care. Not only do patients worry about the physical toxicity of cancer treatment, but they also have to worry about financial toxicity. I’m honored to be a part of The Samfund’s mission to reduce the financial toxicity experienced by cancer survivors and to ensure expenses do not stand between a patient and the best possible treatment.”
Communication gaps were also highlighted in the research that came out of The Samfund’s research study. Many young adults faced issues with initiating a conversation around finances with their doctors; they were ashamed or reluctant to start any financial conversation with their care provider. In his own research studies, Zafar has identified this disconnect—51% of cancer patients included in the study wanted to discuss cost considerations with their doctors, but only 19% actually do.
Samantha Watson, founder and CEO of The Samfund, said, “With Dr Zafar advising us on promoting adherence to medical treatment and new approaches to financial toxicity, we are better poised to help young adult survivors avoid it in the first place. We hear stories every day from individuals who are forgoing follow-up exams with their doctors, dental and mental health care, and facing hard choices between paying medical bills and their grocery bills.”
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More